Oral Adverse Events (OAE) of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA)

Disproportionality Analysis of the FDA Adverse Event Reporting System (2005–2025)”</b>. The files were generated from publicly available FAERS quarterly data and include results from the primary, sensitivity, interclass, and within-class disproportionality analyses, together with time-to-onset and longitudinal reporting analyses.

Oral adverse events were screened using 614 predefined MedDRA Preferred Terms, and analyses were performed across GLP-1 RA class, active-ingredient, and individual-product levels. The deposited files are intended to support transparency, reproducibility, and secondary verification of the reported findings. Raw FAERS source files are not redistributed here and remain publicly available from the U.S. Food and Drug Administration.</p>